A bold, clear opening statement sets the tone: targeting the MYC pathway could unlock a new lifeline for triple-negative breast cancer that has stopped responding to existing PARP inhibitors.
But here’s where it gets controversial: new evidence suggests that Omomyc, a direct MYC inhibitor, not only damages cancer DNA but also boosts the effectiveness of PARP inhibitors, potentially resensitizing stubborn tumors. This combination could redefine treatment for patients with drug-resistant TNBC by attacking cancer cells from two angles at once.
A recent preclinical study from the Vall d’Hebron Institute of Oncology (VHIO) demonstrates that Omomyc—also known as OMO-103—induces DNA damage in cancer cells and enhances the activity of PARP inhibitors. Omomyc has the distinction of being the first direct MYC inhibitor to advance to a phase I clinical trial, with additional trials ongoing in pancreatic cancer and osteosarcoma. In the study, Omomyc increased DNA damage while decreasing the expression of DNA repair genes, creating a vulnerability that PARP inhibitors can exploit.
Understanding MYC’s dual role helps explain why this strategy is compelling. MYC drives cell division and proliferation, yet it also participates in DNA damage response pathways. On one hand, it promotes replication stress and genomic instability; on the other, it supports certain DNA repair mechanisms. This paradox puts cancer cells in a precarious balance, making them particularly susceptible when both MYC activity and DNA repair are simultaneously targeted.
In this research, TNBC models—representing roughly 15–20% of breast cancers and known for their aggressiveness and limited options—were used to test the combination. While PARP inhibitors help BRCA1/2-mutant patients, resistance often emerges. The scientists found that Omomyc alone lowered DNA repair gene activity and increased DNA damage. When paired with PARP inhibitors, the effect was markedly stronger, both in lab dishes and in animal models, leading to higher tumor cell death and better control of disease compared with either treatment alone.
Significantly, PARP-inhibitor–resistant tumors showed higher MYC activity, and Omomyc managed to overcome this resistance. Pre-treatment tumor gene expression related to MYC also helped predict which tumors would respond to PARP inhibitors, offering a potential biomarker avenue to guide therapy.
This work positions Omomyc as a promising agent to resensitize PARP-resistant TNBC by acting as a DNA-damaging partner to PARPi treatment. While these findings are preclinical, they lay a strong foundation for future clinical trials exploring MYC inhibition in combination with PARP inhibitors for patients with this challenging breast cancer subtype.
What this means going forward is both exciting and debatable: combining a MYC inhibitor with PARP inhibition could become a viable strategy for overcoming drug resistance in TNBC, but questions remain about safety, optimal dosing, and which patients will benefit most. Could this approach extend to other MYC-driven cancers? How best to identify responders and monitor early signals of benefit? Share your thoughts and perspectives in the comments on whether this combination should move swiftly into broader clinical testing or proceed with cautious, stepwise validation.
